Cargando…

Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1

Agonists of glucocorticoid receptor (GR) are frequently given to cancer patients with platinum-containing chemotherapy to reduce inflammation, but how GR influences tumor growth in response to platinum-based chemotherapy such as cisplatin through inflammation-independent signaling remains largely un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Chaoyun, Kang, JiHoon, Hwang, Jung Seok, Li, Jie, Boese, Austin C., Wang, Xu, Yang, Likun, Boggon, Titus J., Chen, Georgia Z., Saba, Nabil F., Shin, Dong M., Magliocca, Kelly R., Jin, Lingtao, Kang, Sumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368102/ https://www.ncbi.nlm.nih.gov/pubmed/34400618 http://dx.doi.org/10.1038/s41467-021-24845-8

Ejemplares similares

Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis
por: Boese, Austin C., et al.
Publicado: (2023)

EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer
por: Kang, JiHoon, et al.
Publicado: (2022)

Mitochondrial metabolism-mediated redox regulation in cancer progression
por: Boese, Austin C., et al.
Publicado: (2021)

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016)

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
por: Takekuma, Munetaka, et al.
Publicado: (2015)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity
por: Martinho, Nuno, et al.
Publicado: (2019)

Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
por: Möltgen, Sophie, et al.
Publicado: (2020)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer
por: Clarisse, Dorien, et al.
Publicado: (2021)

Association Between Visceral Hypersensitivity in Irritable Bowel Syndrome, Intestinal Microbiota, and Mast Cells: How to Detect Mast Cells Using Confocal Microscopy
por: Lee, Kang Nyeong, et al.
Publicado: (2021)

Identification of Cisplatin-Binding Proteins Using Agarose Conjugates of Platinum Compounds
por: Karasawa, Takatoshi, et al.
Publicado: (2013)

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer
por: Mahapatra, Elizabeth, et al.
Publicado: (2022)

p190RhoGAP proteins contain pseudoGTPase domains
por: Stiegler, Amy L., et al.
Publicado: (2017)

SH2 Domain Binding: Diverse FLVRs of Partnership
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2020)

The cerebral cavernous malformations proteins
por: Li, Xiaofeng, et al.
Publicado: (2015)

Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.
por: Stewart, D. J., et al.
Publicado: (1995)

Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin
por: Kutwin, Marta, et al.
Publicado: (2014)

Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer
por: Malone, Eoghan R., et al.
Publicado: (2021)

Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity
por: Babolmorad, Ghazal, et al.
Publicado: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Protective effect of Korean Red Ginseng against glucocorticoid-induced osteoporosis in vitro and in vivo
por: Kim, Jinhee, et al.
Publicado: (2014)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
por: Kim, Ki Hong, et al.
Publicado: (2015)

Immunoprofiling of human uterine mast cells identifies three phenotypes and expression of ERβ and glucocorticoid receptor
por: De Leo, Bianca, et al.
Publicado: (2017)

Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Li, Zhiru, et al.
Publicado: (2022)

Ultrasmall, Coating-Free, Pyramidal Platinum Nanoparticles for High Stability Fuel Cell Oxygen Reduction
por: Mastronardi, Valentina, et al.
Publicado: (2022)

Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin
por: C̆emaz̆ar, M, et al.
Publicado: (1999)

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.
por: Guchelaar, H. J., et al.
Publicado: (1992)

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
por: Holford, J., et al.
Publicado: (1998)

Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.
por: Meijer, C., et al.
Publicado: (1997)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation
por: Sun, Si, et al.
Publicado: (2018)

Flow Cytometric Analyses of the Characteristics of Tumor Cells Treated with Two Platinum Compounds: 1,1‐Cyclobutanedicarboxylato(2‐aminomethylpyrrolidine)‐platinum(II) and Cisplatin
por: Inoue, Shoichi, et al.
Publicado: (1992)

Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2019)

Correction: Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2020)

Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP, and Dok1
por: Vish, Kimberly J., et al.
Publicado: (2023)

Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin
por: Hamilton, Gerhard
Publicado: (2014)

Simple Trans-Platinum Complex Bearing 3-Aminoflavone Ligand Could Be a Useful Drug: Structure-Activity Relationship of Platinum Complex in Comparison with Cisplatin
por: Fabijańska, Małgorzata, et al.
Publicado: (2020)

Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
por: Xu, Manman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2pfdbna6kvq4f0a8cu5f75hh9c